Outcomes in COVID-19 mebendazole studies

All studies   Exclusions   Mortality   Ventilation   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 62% 3 411 Improvement, Studies, Patients Relative Risk Mortality 51% 1 157 Ventilation 63% 1 157 Hospitalization 31% 2 342 Viral clearance 85% 1 69 RCTs 85% 1 69 Early 68% 2 254 Late 51% 1 157 Mebendazole for COVID-19 c19early.org November 2025 after exclusions Favorsmebendazole Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Tau​2​ = 0.01, I​2​ = 2.1%, p = 0.042 Early treatment 68% 0.32 [0.11-0.96] 3/128 6/126 68% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 62% 0.38 [0.17-0.88] 6/196 14/215 62% lower risk 3 mebendazole COVID-19 studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.023 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 67% 0.33 [0.11-0.99] 3/102 8/124 67% lower risk 2 mebendazole COVID-19 studies after exclusions c19early.org November 2025 Tau​2​ = 0.05, I​2​ = 7.6%, p = 0.047 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 51% 0.49 [0.14-1.78] 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk 1 mebendazole COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 63% 0.37 [0.08-1.74] 2/68 7/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Late treatment 63% 0.37 [0.08-1.74] 2/68 7/89 63% lower risk All studies 63% 0.37 [0.08-1.74] 2/68 7/89 63% lower risk 1 mebendazole COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.21 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment 52% 0.48 [0.12-1.88] 3/94 6/91 52% lower risk Galal 30% 0.70 [0.57-0.87] hosp. time 68 (n) 89 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Late treatment 30% 0.70 [0.57-0.87] 68 (n) 89 (n) 30% lower risk All studies 31% 0.69 [0.56-0.86] 3/162 6/180 31% lower risk 2 mebendazole COVID-19 hospitalization results c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00065 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment 52% 0.48 [0.12-1.88] 3/94 6/91 52% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 51% 0.49 [0.19-1.24] 6/162 14/180 51% lower risk 2 mebendazole COVID-19 serious outcomes c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.13 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 43% 0.57 [0.41-0.80] recov. time 94 (n) 91 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Early treatment 43% 0.57 [0.41-0.80] 94 (n) 91 (n) 43% lower risk All studies 43% 0.57 [0.41-0.80] 94 (n) 91 (n) 43% lower risk 1 mebendazole COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.001 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk All studies 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk 1 mebendazole COVID-19 viral clearance result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Early treatment 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk All studies 85% 0.15 [0.02-0.94] 34 (n) 35 (n) 85% lower risk 1 mebendazole COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.042 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) Tau​2​ = 0.01, I​2​ = 2.1%, p = 0.042 Early treatment 68% 0.32 [0.11-0.96] 3/128 6/126 68% lower risk Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.28 Late treatment 51% 0.49 [0.14-1.78] 3/68 8/89 51% lower risk All studies 62% 0.38 [0.17-0.88] 6/196 14/215 62% lower risk 3 mebendazole COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.023 Effect extraction pre-specified(most serious outcome) Favors mebendazole Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Galal 52% 0.48 [0.12-1.88] hosp. 3/94 6/91 Improvement, RR [CI] Treatment Control Galal 43% 0.57 [0.41-0.80] recov. time 94 (n) 91 (n) El-Tanani (DB RCT) 85% 0.15 [0.02-0.94] viral load 34 (n) 35 (n) El-Tanani (DB RCT) 59% 0.41 [0.09-1.98] viral+ 2/34 5/35 Galal 51% 0.49 [0.14-1.78] death 3/68 8/89 Galal 63% 0.37 [0.08-1.74] ventilation 2/68 7/89 Galal 30% 0.70 [0.57-0.87] hosp. time 68 (n) 89 (n) Mebendazole COVID-19 outcomes c19early.org November 2025 Favors mebendazole Favors control